Silence Therapeutics (SLN) Retained Earnings (2018 - 2026)

Silence Therapeutics has reported Retained Earnings for 9 years, with the latest figure at -$3.4 million in Q1 2026.

• Quarterly Retained Earnings rose 99.33% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.4 million (up 99.33% YoY) and the FY2025 annual result came in at -$562.6 million, down 4675.25% from the prior year.
• Retained Earnings improved to -$3.4 million in Q1 2026 per SLN's latest filing, from -$562.6 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$3.4 million in Q1 2026 and troughed at -$562.6 million in Q4 2025.
• A 5-year average of -$356.0 million and a median of -$440.3 million in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings slumped 4675.25% in 2025, then soared 99.33% in 2026.
• Over 5 years, Retained Earnings stood at -$308.8 million in 2022, then declined by 22.43% to -$378.1 million in 2023, then jumped by 96.88% to -$11.8 million in 2024, then plunged by 4675.25% to -$562.6 million in 2025, then jumped by 99.4% to -$3.4 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$3.4 million, -$562.6 million, and -$550.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.